Literature DB >> 12427334

Failure of a low virulence Streptococcus gallolyticus serotype 1 strain to immunize pigeons against streptococcosis.

Anja Kimpe1, K Hermans, P De Herdt, F Haesebrouck.   

Abstract

Ten pigeons were inoculated intravenously with the low virulence Streptococcus gallolyticus strain PDH 827, which belongs to serotype 1, supernatant phenotype A(-)T2. The birds did not develop clinical disease but shed S. gallolyticus in their faeces, and antibodies against the bacterium were detected in post-inoculation plasma samples of all birds. Seven weeks later, these pigeons, as well as 14 control pigeons, were challenged intravenously with the highly virulent S. gallolyticus strain STR 357, which also belongs to serotype 1 but to the supernatant phenotype A(+)T1. Post-inoculation morbidity in the immunized group amounted to 90%, demonstrating that no protective immunity had been built up after the first infection. These findings indicate that serotype-specific antigens are not, or at least not solely, involved in induction of protection against S. gallolyticus septicaemia in pigeons.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427334     DOI: 10.1080/0307945021000005770

Source DB:  PubMed          Journal:  Avian Pathol        ISSN: 0307-9457            Impact factor:   3.378


  3 in total

1.  Geno- and phenotypic diversity of avian isolates of Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis) and associated diagnostic problems.

Authors:  M S Chadfield; J P Christensen; A Decostere; H Christensen; M Bisgaard
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

Review 2.  Bacterial vaccines in poultry.

Authors:  Nagwa S Rabie; Zeinab M S Amin Girh
Journal:  Bull Natl Res Cent       Date:  2020-01-29

Review 3.  The Road to Infection: Host-Microbe Interactions Defining the Pathogenicity of Streptococcus bovis/Streptococcus equinus Complex Members.

Authors:  Christoph Jans; Annemarie Boleij
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.